heart failure with preserved ejection fraction

Tirzepatide’s Efficacy in HFpEF and Obesity: Unraveling Diabetes’ Influence from the SUMMIT Trial

By MedXY 09/17/2025

The SUMMIT trial reveals that tirzepatide improves heart failure outcomes and quality of life in obese HFpEF patients with or without type 2 diabetes, despite attenuated weight loss in diabetic patients.

Cardiology news Specialties

Evaluating β-Blocker Use and Health Status in Patients with Heart Failure with Preserved Ejection Fraction: Insights from the TOPCAT Trial

By MedXY 09/11/2025

This analysis of the TOPCAT trial cohort evaluates the association between β-blocker use and health status in HFpEF patients, revealing no significant impact on baseline quality of life or modification of spironolactone benefits.

Cardiology Clinical Updates news Specialties

Volenrelaxin in HFpEF: Unexpected Worsening of Congestion Despite Improvements in Left Atrial Function

By MedXY 09/02/2025

This phase 2 trial shows that volenrelaxin, a long-acting relaxin analog, failed to improve overall congestion or kidney function in HFpEF patients and was linked to worsening congestion and safety signals, despite modest left atrial function improvement at low dose.

Cardiology Clinical Updates news Specialties

Semaglutide and Tirzepatide Significantly Reduce Hospitalization and Mortality in Cardiometabolic HFpEF Patients: Real-World Evidence

By MedXY 08/31/2025

Real-world analysis shows semaglutide and tirzepatide reduce hospitalization for heart failure or all-cause mortality by over 40% in patients with cardiometabolic HFpEF, with no significant difference between the two drug options.